Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dao-Xing Deng, Hong-Hu Zhu, Yan-Rong Liu, Ying-Jun Chang, Guo-Rui Ruan, Jin-Song Jia, Hao Jiang, Qian Jiang, Xiao-Su Zhao & Xiao-Jun Huang. (2019) Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. Leukemia & Lymphoma 60:9, pages 2181-2189.
Read now
Read now
Articles from other publishers (20)
Zhengyu Yu, Li Xie, Jing Zhang, Hua Lin & Ting Niu. (2023) The evolution of minimal residual disease: key insights based on a bibliometric visualization analysis from 2002 to 2022. Frontiers in Oncology 13.
Crossref
Crossref
Bouchra Badaoui, Ivan Sloma & Sihem Tarfi. (2023) Suivi de la maladie résiduelle dans les leucémies aiguës myéloïdes. Revue Francophone des Laboratoires 2023:551, pages 64-74.
Crossref
Crossref
Alexandra Teixeira, Luís Carreira, Sara Abalde-Cela, Belém Sampaio-Marques, Anabela C. Areias, Paula Ludovico & Lorena Diéguez. (2023) Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. Cancers 15:5, pages 1362.
Crossref
Crossref
Hanaa Mahmoud Donia, Nada Mahmoud Elsweify, Nahla Mohamed Farahat & Eman Attia Nadwan. (2022) Wilms tumor 1 gene expression in acute myeloid leukemia: prognostic significance and usefulness in minimal residual disease monitoring—a case–control study. Egyptian Journal of Medical Human Genetics 23:1.
Crossref
Crossref
Katalin Kelemen. (2022) The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms. Life 12:1, pages 109.
Crossref
Crossref
Salvatore Leotta, Annalisa Condorelli, Roberta Sciortino, Giulio Antonio Milone, Claudia Bellofiore, Bruno Garibaldi, Giovanni Schininà, Andrea Spadaro, Alessandra Cupri & Giuseppe Milone. (2022) Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives. Journal of Clinical Medicine 11:1, pages 253.
Crossref
Crossref
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippé, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian SchwarzerCosta Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-BuskeFrancesco Buccisano. (2022) Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HemaSphere 6:1, pages e676.
Crossref
Crossref
Myint Myat Khine Aung, Megan L. Mills, Joana Bittencourt‐Silvestre & Karen Keeshan. (2021) Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia. Molecular Oncology 15:9, pages 2253-2272.
Crossref
Crossref
Tibor Hianik. (2021) Advances in Electrochemical and Acoustic Aptamer-Based Biosensors and Immunosensors in Diagnostics of Leukemia. Biosensors 11:6, pages 177.
Crossref
Crossref
Guang Yang & Linsheng Zhang. 2021. Practical Oncologic Molecular Pathology. Practical Oncologic Molecular Pathology
275
304
.
Eddy N de Boer, Lennart F Johansson, Kim de Lange, Anneke G Bosga-Brouwer, Eva van den Berg, Birgit Sikkema-Raddatz & Cleo C van Diemen. (2020) Detection of Fusion Genes to Determine Minimal Residual Disease in Leukemia Using Next-Generation Sequencing. Clinical Chemistry 66:8, pages 1084-1092.
Crossref
Crossref
Minhua Su, Hui Cheng & Tao Cheng. (2020) Preleukemic stem cells: leave it or not?. Blood Science 2:2, pages 54-58.
Crossref
Crossref
Huasheng Liu, Xiaoning Wang, Hailing Zhang, Jincheng Wang, Ying Chen, Tiantian Ma, Jing Shi, Ya Kang, Jieying Xi, Mengchang Wang & Mei Zhang. (2019) Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation. Molecular Medicine Reports.
Crossref
Crossref
Anne Stidsholt Roug & Hans Beier Ommen. (2019) Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia. Current Treatment Options in Oncology 20:4.
Crossref
Crossref
Ran Zhang, Xuan Lu, Huafang Wang, Yong You, Zhaodong Zhong, Sibin Zang, Chun Zhang, Wei Shi, Junying Li, Qiuling Wu, Jun Fang & Linghui Xia. (2019) Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease. Biology of Blood and Marrow Transplantation 25:1, pages 47-55.
Crossref
Crossref
Fabio Forghieri, Patrizia Comoli, Roberto Marasca, Leonardo Potenza & Mario Luppi. (2018) Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. International Journal of Molecular Sciences 19:11, pages 3492.
Crossref
Crossref
Byong Chul Yoo, Kyung-Hee Kim, Sang Myung Woo & Jae Kyung Myung. (2018) Clinical multi-omics strategies for the effective cancer management. Journal of Proteomics 188, pages 97-106.
Crossref
Crossref
Farhad RavandiRoland B. Walter & Sylvie D. Freeman. (2018) Evaluating measurable residual disease in acute myeloid leukemia. Blood Advances 2:11, pages 1356-1366.
Crossref
Crossref
Ya-Zhen Qin, Yao Chen, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Xiao-Su Zhao, Kai-Yan Liu & Xiao-Jun Huang. (2018) Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 24:1, pages 163-168.
Crossref
Crossref
Lin Wang, Xiao-yan Wu, Run-ming Jin, Bing-yu Zhang & Yi-ning Qiu. (2017) Trisomy 21 with t(5; 11) chromosomal translocation as new unfavorable cytogenetic abnormalities in pediatric acute myeloid leukemia type M2: One case report of nine-year follow-up and literature review. Current Medical Science 37:5, pages 807-810.
Crossref
Crossref